- Conditions
- ADHD
- Interventions
- NRCT-101-SR, Placebo
- Drug
- Lead sponsor
- Neurocentria, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,204
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
- Conditions
- Kidney Transplant
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Neuroblastoma
- Interventions
- Naxitamab
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2036
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more
- Conditions
- Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
- Interventions
- Finerenone (Kerendia, BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
- Conditions
- Esophageal Cancer
- Interventions
- Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.
- Device
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 50 participants
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- B-MPH
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Post Operative Pain
- Interventions
- Methadone Hydrochloride
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Asthma
- Interventions
- QAW039 150 mg, QAW039 450 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 2,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Encinitas, California • Newport Beach, California + 41 more
- Conditions
- Traumatic Brain Injury, Attention Deficit Disorder
- Interventions
- Lisdexamfetamine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- brinzolamide 1.0%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Bipolar Disorder
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lymphoma, Hodgkin Disease
- Interventions
- tumor tissue aspiration, phlebotomy
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Interventions
- Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
- Drug
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 374
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity
- Interventions
- methylphenidate hydrochloride (Jornay PM)
- Drug
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Refractive Errors, Asthenopia
- Interventions
- Spectacle Lenses
- Device
- Lead sponsor
- American Optometric Association
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetic Macular Edema
- Interventions
- Aliskiren, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
- Conditions
- Kidney Transplant Recipient
- Interventions
- Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
- Biological · Other
- Lead sponsor
- Mark Stegall
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Graft Versus Host Disease
- Interventions
- stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Miami, Florida • Las Vegas, Nevada
- Conditions
- GERD in Infants
- Interventions
- Omeprazole, AR formula
- Drug · Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Day to 8 Months
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Attention-Deficit Hyperactivity Disorder
- Interventions
- Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 3 Years and older
- Enrollment
- 1,091 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland